Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco (NYSE: ELAN) announced Emergency Use Authorization from the FDA for Negasunt Powder and an EPA Section 18 exemption for Tanidil to prevent and treat New World screwworm in multiple livestock species, effective April 27, 2026.
Both products will be distributed through APHIS and the National Veterinary Stockpile, used under coordination with state and tribal officials, and include strict safety, use, and withdrawal limitations.
Elanco (NYSE: ELAN) announced Emergency Use Authorization from the FDA for Negasunt Powder and a Section 18 EPA emergency exemption for Tanidil to prevent and treat New World screwworm infestations in multiple livestock species.
Products will be distributed through APHIS and the National Veterinary Stockpile; Tanidil exemption effective April 27, 2026 through April 27, 2029. Safety limits, PPE requirements, slaughter-withholding periods and use restrictions are included.
National Veterinary Associates (ACHC) named Todd S. Young as Chief Financial Officer, effective May 1, 2026. He will report to CEO John Bruno and join the executive leadership team. Young brings more than 25 years in human and animal healthcare finance, including prior CFO roles at Acadia Healthcare (NASDAQ: ACHC) and Elanco (NYSE: ELAN).
Young said he looks forward to strengthening NVA's financial foundation as the company continues investing across its care network.
Elanco (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026 and will host a conference call the same day.
The conference call begins at 8:00 a.m. Eastern time, with a live webcast and subsequent replay accessible via the company investor website.
Elanco (NYSE: ELAN) launched the Advantage™ Collar for Dogs on April 9, 2026, offering four months of continuous protection against fleas, ticks and repelling mosquitoes* for dogs and puppies 12 weeks and older.
The adjustable, time-release collar strengthens Elanco's 25-year Advantage brand, will be sold at pet specialty, dollar, grocery and mass retailers, and has a suggested retail price below $25**. Excludes California for the mosquito claim.
Elanco (NYSE: ELAN) reported Q4 2025 revenue of $1,144M (+12% reported, +9% organic CC) and full-year 2025 revenue of $4,715M (+6% reported, +7% organic CC). Innovation revenue exceeded target at $892M and 2026 innovation target raised to $1.15B. Reported net loss was $276M in Q4 and $232M for 2025; adjusted EBITDA was $189M Q4 and $901M FY. Full-year 2026 guidance: revenue $4,950–$5,020M, adjusted EBITDA $955–$985M, adjusted EPS $1.00–$1.06, and year-end net leverage target 3.1x–3.3x.
Elanco (NYSE: ELAN) announced management participation in multiple investor conferences between Feb 26 and Mar 17, 2026. Executives including Jeff Simmons, Bob VanHimbergen, Luke Smith and Bobby Modi will appear in scheduled fireside chats with banks and healthcare conferences.
Live audio webcasts will be available in the Events and Presentations section of Elanco's investor website; replays will be posted for a limited time after each event.
Elanco (NYSE: ELAN) announced on Feb 13, 2026 that R. David Hoover and Deborah Kochevar will not stand for re-election at the 2026 Annual Meeting in May. Hoover is retiring after joining the board in Sept 2018 as founding chairman; Kochevar joined in March 2019.
The company said Hoover helped guide the spin-off and early public years, and Kochevar chaired the Innovation, Science and Technology committee. Following these departures, the board will consist of nine directors.
Elanco (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A conference call with the investment community and media will be held the same day starting at 8:00 a.m. Eastern Standard Time. Investors, media, and the public can access a live webcast via Elanco's investor website and a replay will be available on the site shortly after the call.
Elanco (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 p.m. EST).
A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, and a replay will be available for a limited time after the event.